Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Roche is jumping back into the GLP-1 space with a definitive merger agreement to acquire Carmot Therapeutics for $2.7 billion upfront. The deal gives Roche control of Carmot’s metabolic drug pipeline, which comprises three GLP-1 agonists for obesity and related comorbidities.

Under the terms of the merger, Carmot’s equity holders…
Click here to view original post